Patrick Forde, MBBCh offers an overview of current standard-of-care treatments as well as emerging immunotherapy options for treating early-stage, resectable non-small cell lung cancer.
Patrick Forde, MBBCh
Patrick Forde, MBBCh, is the codirector, Division of Upper Aerodigestive Malignancies, and professor of oncology at Johns Hopkins Medicine.
Articles by Patrick Forde, MBBCh
Patrick Forde, MBBCh, discusses the results of the TRIDENT-1 trial that led to the approval of repotrectinib for patients with metastatic ROS1 positive NSCLC.